DIANTHUS THERAPEUTICS ($DNTH) posted quarterly earnings results on Thursday, August 7th. The company reported earnings of -$0.88 per share, beating estimates of -$0.89 by $0.01. The company also reported revenue of $190,000, missing estimates of $881,616 by $-691,616.
You can see Quiver Quantitative's $DNTH stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
DIANTHUS THERAPEUTICS Hedge Fund Activity
We have seen 38 institutional investors add shares of DIANTHUS THERAPEUTICS stock to their portfolio, and 49 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DEEP TRACK CAPITAL, LP added 2,357,702 shares (+inf%) to their portfolio in Q1 2025, for an estimated $42,768,714
- POINT72 ASSET MANAGEMENT, L.P. added 1,293,344 shares (+668.0%) to their portfolio in Q1 2025, for an estimated $23,461,260
- AVIDITY PARTNERS MANAGEMENT LP removed 1,152,098 shares (-40.1%) from their portfolio in Q1 2025, for an estimated $20,899,057
- RA CAPITAL MANAGEMENT, L.P. added 1,000,333 shares (+53.6%) to their portfolio in Q1 2025, for an estimated $18,146,040
- BRAIDWELL LP removed 831,234 shares (-68.9%) from their portfolio in Q1 2025, for an estimated $15,078,584
- RTW INVESTMENTS, LP removed 666,667 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $12,093,339
- VESTAL POINT CAPITAL, LP added 625,069 shares (+58.1%) to their portfolio in Q1 2025, for an estimated $11,338,751
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
DIANTHUS THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $DNTH in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- William Blair issued a "Outperform" rating on 07/02/2025
- Baird issued a "Outperform" rating on 05/13/2025
- HC Wainwright & Co. issued a "Buy" rating on 05/13/2025
- Wedbush issued a "Outperform" rating on 03/12/2025
- Guggenheim issued a "Buy" rating on 03/12/2025
To track analyst ratings and price targets for DIANTHUS THERAPEUTICS, check out Quiver Quantitative's $DNTH forecast page.
DIANTHUS THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $DNTH recently. We have seen 4 analysts offer price targets for $DNTH in the last 6 months, with a median target of $45.0.
Here are some recent targets:
- Joel Beatty from Baird set a target price of $50.0 on 05/13/2025
- Swayampakula Ramakanth from HC Wainwright & Co. set a target price of $40.0 on 05/13/2025
- Laura Chico from Wedbush set a target price of $36.0 on 03/12/2025
- Yatin Suneja from Guggenheim set a target price of $84.0 on 03/12/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
